Navigation Links
Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease
Date:4/2/2008

Patients on immunosuppressants should seek medical attention at any sign of infection

ROCHESTER, Minn., April 2, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study finds that patients who are 50 or older and take multiple immunosuppressive medications for inflammatory bowel disease have a higher risk for developing infections. The study is published in this month's issue of Gastroenterology.

More than 1 million Americans are believed to have ulcerative colitis or Crohn's disease, the most common forms of inflammatory bowel disease. These conditions inflame the lining of the digestive tract and cause severe bouts of watery diarrhea and abdominal pain. The cause of these conditions is not known, but the most common theory is that the immune system of patients with inflammatory bowel disease reacts abnormally to bacteria in the gut.

"Patients with inflammatory bowel disease are often treated with a combination of immunosuppressive medications to help relieve symptoms," says Edward Loftus, M.D. a Mayo Clinic gastroenterologist and an author of this study. "Since these medications compromise immune reactions in the body, patients can develop what are called opportunistic infections, or infections from common organisms that would not affect individuals with healthy immune systems."

Dr. Loftus and a team of Mayo Clinic researchers set out to identify and quantify the risk factors that are associated with opportunistic infections in inflammatory bowel disease patients. They studied the medical records of 300 patients with inflammatory bowel disease. One hundred of these patients had contracted opportunistic infections and 200 patients had no history of these infections. The team found that patients who were age 50 or older were three times more likely to have infections than younger patients. Additionally, patients on one immunosuppressive medication were three times more likely to develop opportunistic infections than those on none. Patients on two or three different immunosuppressive medications were 14 times more likely to develop opportunistic infections than those on none.

"This study shows that patients with inflammatory bowel disease who are on immunosuppressive medications should have a low threshold for seeking medical attention at any sign of infection, such as cough or fever," says Dr. Loftus. "For the medical community, this is another example of the need to be cognizant of the potential risks of combination immunosuppressive therapies."

Other members of the Mayo Clinic research team included Murat Toruner, M.D.; W. Scott Harmsen; Alan Zinsmeister, Ph.D.; Robert Orenstein, D.O.; William Sandborn, M.D.; Jean-Frederic Colombel, M.D.; and Laurence Egan, M.D.

Each year, physicians at Mayo Clinic's campuses in Arizona, Florida and Minnesota treat thousands of patients who have digestive diseases. For more information on the treatment of digestive diseases at Mayo Clinic, visit http://www.mayoclinic.org/gi.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.

CONTACT:

Elizabeth Rice

507-284-5005 (days)

507-284-2511 (evenings)

newsbureau@mayo.edu


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: